AMANDA WILFORD: Open Payments
NPI 1508156506 · MILAN, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$520 in 35 payments from 8 companies in 2025. Trend: 2023 $139 · 2024 $193 · 2025 $520
Food & beverage: $520
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 12 | $162 |
| Vanda Pharmaceuticals Inc. | 11 | $158 |
| Exact Sciences Corporation | 3 | $56 |
| AstraZeneca Pharmaceuticals LP | 3 | $55 |
| ABBVIE INC. | 3 | $46 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
| PFIZER INC. | 1 | $15 |
Products named: CAPLYTA, FANAPT, BREZTRI, HETLIOZ, VRAYLAR, The Cologuard Plus Collection Kit, Cologuard Collection Kit, REXULTI.
Industry payments across MO — which companies pay providers there.
